TEPMETKO

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Croatia, Estonia, Finland, Israel, Italy, Japan, Lithuania, Poland.

Active ingredients

The drug TEPMETKO contains one active pharmaceutical ingredient (API):

1	Tepotinib UNII VY5YX2TQ1F - TEPOTINIB HYDROCHLORIDE
	Tepotinib is a reversible Type I adenosine triphosphate (ATP)-competitive small molecule inhibitor of MET. Tepotinib blocked MET phosphorylation and MET-dependent downstream signalling in a dose-dependent manner. Tepotinib demonstrated pronounced anti-tumour activity in tumours with oncogenic activation of MET, such as METex14 skipping alterations.
	Read more about Tepotinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TEPMETKO Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
TEPMETKO Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX21		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX21

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	525421090053002
EE	Ravimiamet	1876293
FI	Lääkealan turvallisuus- ja kehittämiskeskus	176387
IL	מִשְׂרַד הַבְּרִיאוּת	9037
IT	Agenzia del Farmaco	049967019
JP	医薬品医療機器総合機構	4291065F1024
LT	Valstybinė vaistų kontrolės tarnyba	1094284
PL	Rejestru Produktów Leczniczych	100466998
US	FDA, National Drug Code	44087-5000